CDK4/6 inhibitors may be a future treatment modality for glioma patients with pathogenic CDKN2A variants causing melanoma-astrocytoma syndrome [77] detected here in one CDKN2A GV carrier with an anaplastic astrocytoma and a melanoma. This evidence concerns the gene CDKN2A and central nervous system cancer.